The 23andMe Data Sale to TTAM, Explained

In mid-2025, following the Chapter 11 sale process that began with the March 2025 filing, TTAM Research Institute acquired 23andMe’s genetic data and core operating assets. TTAM is a nonprofit founded by 23andMe co-founder Anne Wojcicki. The consumer service continued operating under the new ownership, but the legal entity holding roughly 14 million genotype profiles is now different from the company most users originally signed up with.

What happened

The path to TTAM ran through the bankruptcy court rather than around it. Wojcicki’s pre-bankruptcy bids to take 23andMe private had failed at the board level in 2024 and early 2025. After the company filed Chapter 11, a court-supervised sale process invited competing bids for the business and its assets, including the genetic data.

TTAM Research Institute emerged as the buyer, with a structure framed as research focused and nonprofit rather than venture backed and revenue maximizing. The bankruptcy court approved the sale order, and the closing transferred ownership of 23andMe’s data and operating assets to TTAM in mid-2025. We covered the bankruptcy itself in the 23andMe bankruptcy and your data.

The consumer-facing site, the existing accounts, and the testing pipeline continued without interruption through the sale, which is consistent with how bankruptcy sales of operating businesses usually work.

What it means for your data

Three things changed in ways that matter for privacy.

The legal entity is different. The terms of service and privacy policy you accepted when you tested were a contract with 23andMe, Inc. The data is now held by a nonprofit research institute. Whether the original consents follow the data to the new owner, and on what terms, is a real legal question and one that the sale order addressed with specific provisions. The 23andMe privacy policy and customer notices published after the sale describe how user choices about research participation and deletion carry forward. Read those, not the marketing language, if the detail matters to you.

The corporate mission framing changed. Nonprofit ownership is not by itself a privacy guarantee. A nonprofit can still be breached, can still receive law enforcement requests, and can still change its policies. What it does, on paper, is reduce the pressure to monetize the data through commercial partnerships in the way a publicly traded company might. Whether that holds in practice is something we will track over time.

Users retained their core controls. Account deletion, raw data download, and the right to opt out of research participation continued to be supported through the sale, per the sale order and post-sale customer notices. If you tested with 23andMe and want to exercise any of those rights, the mechanics are the same as before.

What you can do

If you are reassessing what you want done with your data given the new ownership, two free actions are within your control as of early 2026.

You can download your raw DNA data and keep a local copy independent of any single company.

You can delete your 23andMe account and request destruction of your biological sample. Account deletion and sample destruction are separate requests, and the original account-level rights continue under the new owner.

For broader context on whether genetic data can be sold at all and what the typical contract says, see can DNA test data be sold. The genetic data privacy hub tracks the situation over time. If you are reassessing 23andMe as a product on the merits, the 23andMe review covers what the test does and how its reports compare to the rest of the field.